Apomorphine (Apokyn) vs Apomorphine (Onapgo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: Dopamine receptor (non-ergoline agonist) · full Parkinson's Disease pipeline

Apomorphine (Apokyn)

Marketed by Supernus Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Weak signal

NCT00142545 · Phase 3 · completed

The study was non-randomized, open-label, and had no comparator arm; all 800 participants received apomorphine. Its primary outcomes focused on safety monitoring, and no primary endpoint results were posted, so there is no controlled comparison showing benefit.

No aligned efficacy figure on record for this race.

Apomorphine (Onapgo)

Marketed by Supernus Pharmaceuticals and partners

Approved in Parkinson's Diseasesmall molecule
Reliable signal

NCT02006121 · Phase 3 · completed

The 12-week blinded phase randomized 107 participants to apomorphine or saline placebo, with participants, care providers, investigators, and outcome assessors masked. The primary clinical endpoint was met: apomorphine produced a greater reduction in daily OFF time than placebo, with a reported p-value of 0.0047, although substantial numbers did not complete the blinded phase.

Reported efficacy

Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Apomorphine Hydrochloride -2.61 Hours (95% CI -3.43 to -1.8) vs Placebo -0.75 Hours (95% CI -1.66 to 0.16) (met)

Result source: NCT02006121

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointApomorphine (Apokyn)Apomorphine (Onapgo)
OFF time, change—Not posted · NCT00200525-2.6 vs -0.8−1.9 vs placebowk 12 · n 53NCT02006121
ON time without troublesome dyskinesia, change—Not posted · NCT00200525—Not reported
UPDRS Part III, change—Not posted · NCT00200525—Not reported
MDS-UPDRS Part II, change—Not posted · NCT00200525—Not reported

OFF time, change

Apomorphine (Apokyn)
—Not posted · NCT00200525
Apomorphine (Onapgo)
-2.6 vs -0.8−1.9 vs placebowk 12 · n 53NCT02006121

ON time without troublesome dyskinesia, change

Apomorphine (Apokyn)
—Not posted · NCT00200525
Apomorphine (Onapgo)
—Not reported

UPDRS Part III, change

Apomorphine (Apokyn)
—Not posted · NCT00200525
Apomorphine (Onapgo)
—Not reported

MDS-UPDRS Part II, change

Apomorphine (Apokyn)
—Not posted · NCT00200525
Apomorphine (Onapgo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Apomorphine (Apokyn): 4 of 4 rows · Apomorphine (Onapgo): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricApomorphine (Apokyn)Apomorphine (Onapgo)
Dropout rate
20.5%a
NCT01770145 · Phase 4 · registry result, not featured evidence
22.2%
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Discontinued due to AEs
15.7%a
NCT01770145 · Phase 4 · registry result, not featured evidence
11.1%
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Serious AEs
0%a
NCT01770145 · Phase 4 · registry result, not featured evidence
23.5%
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Most frequent reported AEs
a
nausea 19.7%
yawning 7.9%
somnolence 5.5%
NCT01770145 · Phase 4 · registry result, not featured evidence
infusion site nodule 46.9% (placebo 0%)
nausea 20.4% (placebo 9.4%)
somnolence 19.4% (placebo 3.8%)
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Apomorphine (Apokyn)

Time to on Change 37.14 minutes @ 1wk
absolute change · minutes
No placebo or comparator arm
Change from Baseline
NCT01770145 · Phase 4 · registry result, not featured evidence

Apomorphine (Onapgo)

OFF Time -2.61 vs -0.75 placebo hours @ 12wk
absolute change · hours
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
Daily on Time Without Troublesome Dyskinesia 2.9 vs 0.85 placebo hours @ 12wk
absolute change · hours
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3
PGIC 79.1% (n=43) vs 23.5% (n=34) placebo @ 12wk
responder rate · % of participants
NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine (Apokyn)'s landscape · Apomorphine (Onapgo)'s landscape